1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Viking Bolsters MASH Case With 52-Week Histology Data

 
• By Joseph Haas

Viking will look to plan a Phase III program with the FDA after showing 52-week success on MASH resolution and fibrosis reduction with VK2809. The firm still hopes to move forward with a partner.

SC2008_Fatty Liver_274834199_1200.jpg
Viking's 52-week biopsy data bolster case for VK2809 in MASH

Slightly more than one year after reporting 12-week data from its Phase IIb VOYAGE trial showing that VK-2809 can significantly reduce liver fat content in metabolic-associated steatohepatitis (MASH), Viking Therapeutics, Inc. bolstered those findings on 4 June with 52-week, histologic data from the study that also demonstrated a statistically significant benefit on reducing fibrosis.

Key Takeaways

  • Viking reports 52-week biopsy data for VK2809 in MASH, bolstering the case made with 12-week data in 2023 for MASH resolution with the drug.

The data position the San Diego-based firm to seek an end-of-Phase II meeting with the US Food and Drug Administration...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.